MARKET

ZYNE

ZYNE

Zynerba Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.310
-0.160
-4.61%
After Hours: 3.500 +0.19 +5.74% 17:41 04/03 EDT
OPEN
3.480
PREV CLOSE
3.470
HIGH
3.480
LOW
3.230
VOLUME
298.33K
TURNOVER
--
52 WEEK HIGH
16.47
52 WEEK LOW
2.550
MARKET CAP
77.97M
P/E (TTM)
-2.1785
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 7 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average ZYNE stock price target is 15.71 with a high estimate of 26.00 and a low estimate of 4.500.

EPS

ZYNE News

More
  • Zynerba Pharmaceuticals (ZYNE) Gains But Lags Market: What You Should Know
  • Zacks · 1d ago
  • Top Marijuana Stocks on the NASDAQ for April 2020
  • Investopedia · 03/26 18:05
  • Zynerba Pharmaceuticals (ZYNE) Gains But Lags Market: What You Should Know
  • Zacks · 03/25 22:50
  • The Week In Cannabis: Coronavirus Drop, Major Financing Agreements, Psychedelics Getting Hot
  • Benzinga · 03/14 12:53

Industry

Biotechnology & Medical Research
-0.74%
Pharmaceuticals & Medical Research
-0.56%

Hot Stocks

Symbol
Price
%Change

About ZYNE

Zynerba Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company is engaged in developing and commercializing transdermal synthetic cannabinoid treatments for patients with high unmet needs. Its development pipeline includes two product candidates: ZYN002 and ZYN001. ZYN002 is a synthetic cannabidiol (CBD), which is a non-psychoactive cannabinoid, formulated as a patent-protected permeation-enhanced gel for transdermal delivery through the skin and into the circulatory system. ZYN002 is in Phase II clinical development in patients with refractory epilepsy, in patients with osteoarthritis of the knee, as well as in patients with Fragile X syndrome. ZYN001 is a pro-drug of tetrahydrocannabinol (THC) that enables transdermal delivery through the skin and into the circulatory system through a patch. ZYN001 is targeting two pain indications, fibromyalgia and peripheral neuropathic pain.
More

Webull offers kinds of Zynerba Pharmaceuticals Inc stock information, including NASDAQ:ZYNE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ZYNE stock news, and many more online research tools to help you make informed decisions.